Idogen AB (publ)

As of March 31, 2023, Idogen AB (publ) has 104.37M shares outstanding.

These figures are as of March 31, 2023.

As of March 31, 2023, Idogen AB (publ) maintains a current ratio of 1.66, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2023, Idogen AB (publ) posted a negative return on equity (ROE) of -202.72, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -172.11, reflecting losses generated across the asset base.

These figures cover the twelve months ended March 31, 2023. Free cash flow yield is negative at -626.38: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -57.92, meaning Idogen AB (publ) raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Idogen AB (publ)'s most recent stock split took place on May 27, 2020 with a 10:1 split ratio.

As of March 31, 2023, Idogen AB (publ) has an Altman Z-Score of -28.06, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.